ARCH Venture Partners Names Steve Gillis, Co-Founder of Immunex and Corixa, as Venture Partner Tuesday August 2, 12:56 pm ET
SEATTLE, Aug. 2 ARCH Venture Partners announced today that Dr. Steven Gillis, Ph.D., co-founder of Immunex and Corixa Corporations, has joined the firm as a Venture Partner based out of its Seattle office. Dr. Gillis will focus on assisting in the development and growth of ARCH's biotechnology portfolio companies nationwide and will assume Board roles in a number of those companies. He will also be active in the evaluation of new life science technologies. Dr. Gillis is a pioneer within the biotechnology industry and one of its most respected executives, serving as Director of Research and Development, Chief Scientific Officer, and eventually Chairman and CEO of Immunex Corp., which he co-founded in 1981, and which was acquired by Amgen in December 2001. Dr. Gillis also co-founded Corixa Corp. in 1994 where he served as Chairman and CEO. Corixa was acquired by GlaxoSmithKline in July 2005. Robert Nelsen, Managing Director and co-founder of ARCH, said, "Dr. Gillis will bring to ARCH extensive experience in creating and managing biotech companies as well as rapidly developing products from fundamental research. He is that rare combination of successful entrepreneur and scientist, which fits well with ARCH's science- driven approach to venture capital investment. We are delighted to have someone of his caliber and experience join the ARCH team." Dr. Gillis commented, "I look forward to helping ARCH and their portfolio companies. I hope that lessons I have learned in the past 25 years in the industry will be of use, not only to existing organizations, but to companies that may be put together in the next several years." An original recruit to the Fred Hutchinson Cancer Research Center in Seattle, Dr. Gillis maintained an academic laboratory focused on immune regulation. He received his B.A. from Williams College and his Ph.D. from Dartmouth College. About ARCH Venture Partners ARCH Venture Partners focuses on creating early stage technology companies in the life, physical and information sciences, which emanate from universities, national laboratories and corporate research labs. With over $1 billion under management, ARCH has invested in the earliest rounds of more than 120 companies over a 20 year history. Early stage biotechnology investments include Caliper Life Sciences, Adolor, Illumina, deCode Genetics, Aviron (acquired by MedImmune), Array BioPharma, XenoPort, GenVec, Alnylam Pharmaceuticals, Ikaria, NeurogesX, R2 Technology, and Trubion Pharmaceuticals, among others. ARCH was also a seed investor in companies such as New Era of Networks (acquired by Sybase), Nanosys, Impinj, and MicroOptical Devices (acquired by Emcore). www.archventure.com --------------------------------------------------------------------- ----------- Source: ARCH Venture Partners http://www.arizonabiotech.com/ http://groups.yahoo.com/group/biotech-news/ http://www.arizonaentrepreneurs.com/ http://www.azhttp.com/ http://www.arizonabiotech.com/index.php http://www.mail-archive.com/biotech-news@yahoogroups.com/ http://www.mail-archive.com/biotech-news@yahoogroups.com/maillist.html http://www.arizonabiotech.com/ <a href="http://www.arizonabiotech.com/";>Arizona Biotech</a> http://groups.yahoo.com/group/biotech-news/ <a href="http://groups.yahoo.com/group/biotech-news/";>Biotech News</a> http://www.arizonaentrepreneurs.com/ <a href="http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs</a> http://www.azhttp.com/ <a href="http://www.azhttp.com/";>Arizona High Tech</a> Yahoo! Groups Links <*> To visit your group on the web, go to: http://groups.yahoo.com/group/biotech-news/ <*> To unsubscribe from this group, send an email to: [EMAIL PROTECTED] <*> Your use of Yahoo! Groups is subject to: http://docs.yahoo.com/info/terms/
